nightclaude · nightly deep dive · 2026-10-22
Edwards at $88.40: the $50.90B valve pure play growing again
At $88.40, Edwards Lifesciences commands a $50.90B market cap and $47.51B enterprise value for $6.07B of FY2025 revenue at 77.8% gross margin and 29.8% operating margin. The stock is up 16.3% over one year but still down 24.2% over five years, stuck between a $74.66 to $96.29 52 week range and a $101.81 Street target that prices a second act in PASCAL and EVOQUE beyond SAPIEN TAVR.
Edwards Lifesciences was built to do one thing the hard way: replace a failing heart without opening the chest. Founded in 1958 in Irvine, California, with 16,000 employees today, it turned the Edwards SAPIEN family into the default aortic valve against Medtronic Evolut and Abbott Navitor, then extended the fight into PASCAL and EVOQUE for mitral and tricuspid disease and INSPIRIS RESILIA in surgery, producing $6.07B of FY2025 revenue at 77.8% gross margin with $2.94B in cash against only $705.40M of total debt.
At $88.40, worth $50.90B with a $47.51B enterprise value, the market still cannot decide what that focus is worth. The shares are up 16.3% in a year but down 24.2% over five years, trading at 52.62 times trailing earnings against 26.13 times forward earnings and 23.79 times EV to EBITDA, with a $101.81 buy rated target implying the PASCAL and EVOQUE portfolio finally turns a TAVR annuity into a compounder again on 13.6% revenue growth.
History & Ownership
Edwards Lifesciences Corporation was founded in 1958 and is headquartered in Irvine, California, with 16,000 employees. At $88.40 per share, the market values the business at $50.90B with an enterprise value of $47.51B. That scale makes it the structural heart pure play of the medical device world, built around transcatheter aortic valve replacement under the Edwards SAPIEN family, transcatheter mitral and tricuspid repair and replacement under the PASCAL and EVOQUE brands, and surgical valves led by INSPIRIS RESILIA, KONECT RESILIA and MITRIS RESILIA.
The origin story is classic medtech. Founder and hydraulic engineer Miles Lowell Edwards set out in 1958 to build the first artificial heart, per yahoo.com, September 2016. Working with surgeon Albert Starr, the team produced the Starr-Edwards mitral valve, the first successfully implanted prosthetic heart valve, and established Edwards Laboratories in Santa Ana. In 1966 the business was sold to American Hospital Supply Corporation and became American Edwards Laboratories, then passed to Baxter International in 1985.
From Baxter division to independent structural heart leader
Edwards was spun off from Baxter and began trading publicly on the New York Stock Exchange under the ticker EW, per ir.edwards.com, April 2000. The spinoff was finalized March 31, 2000 as a tax free dividend to Baxter holders, with trading beginning in early April 2000, per ir.edwards.com, April 2000. The early 2000 spin history is also summarized as a 2000 separation into an independent public company trading as EW, per zippia.com, July 2023.
Freed from a conglomerate, Edwards narrowed relentlessly to heart valves. The decisive move was the late 2003 acquisition of Percutaneous Valve Technologies, which gave Edwards the transcatheter platform that became SAPIEN, per ocbj.com, May 2010. SAPIEN launched in Europe in 2007, then powered U.S. growth through successive approvals for inoperable, high risk, intermediate risk and ultimately low risk patients, including SAPIEN 3 and SAPIEN 3 Ultra approval for low risk patients in August 2019, per en.wikipedia.org. Management then replicated the playbook beyond aortic stenosis into mitral and tricuspid disease with PASCAL repair and EVOQUE replacement, culminating in the February 2024 FDA approval of the EVOQUE tricuspid valve replacement system as the first transcatheter tricuspid therapy, per en.wikipedia.org.
Ownership and management character
Edwards is a widely held, institutionally owned large cap with negligible insider ownership. The shareholder base is classic for a $50.90B Healthcare compounder, patient, indexed and growth oriented, with no controlling holder.
| Holder type | Stake and scale |
|---|---|
| Institutions | 95.66% held across 1,919 institutions |
| Insiders | 0.195% held |
| Balance sheet imprint | $2.94B cash and cash equivalents against $705.40M total debt |
Leadership reflects continuity and a Credo driven, patient first culture described on its corporate site as guided by its Credo and focused on helping patients, per edwards.com. Chief Executive Officer Bernard J. Zovighian has served as CEO since May 2023 after serving as president, per simplywall.st, June 2026. Board leadership is independent, with Nicholas J. Valeriani as Chair and an independent Board Chair structure in place since 2024, per sec.gov, March 2026. Finance turned over in 2026, with Theodora Mistras appointed corporate vice president and chief financial officer effective at the end of May to succeed Scott Ullem, joining from Viatris where she served as CFO, per sec.gov, May 2026. Characteristically for Edwards, management runs a low leverage balance sheet, funds $1.08B of research and development from a $6.07B revenue base on SEC XBRL definitions, and returns capital through buybacks rather than empire building.
Business Model & Strategy
Edwards Lifesciences is a pure play structural heart monopoly in the making, built around one job: replacing or repairing a failing heart valve without opening the chest. The Irvine company employs 16,000 people and generated $6.07B in FY2025 revenue on SEC EDGAR XBRL facts, up from $5.38B in FY2022 and $6.00B in FY2023, sold in the United States, Europe, Japan and internationally through a direct sales force and independent distributors. At $88.40 on October 21, 2026, the market values that franchise at $50.90B with an enterprise value of $47.51B, or 23.79 times EBITDA, a multiple that only makes sense if transcatheter valves keep taking share from surgery.
What it sells and to whom
The customer is not the patient, it is the hospital heart team, the interventional cardiologist and cardiac surgeon who jointly decide aortic, mitral and tricuspid strategy. Edwards sells them single use implants, delivery catheters and surgical valves:
- Transcatheter aortic valve replacement (TAVR): the Edwards SAPIEN family for minimally invasive replacement of the aortic valve. This is the engine, competing head to head with Medtronic Evolut and Boston Scientific ACURATE and NAVITOR, where iteration, paravalvular leak rates, durability data and proctoring win cases.
- Transcatheter mitral and tricuspid therapies (TMTT): PASCAL for repair and EVOQUE for replacement, plus SAPIEN M3. This is the growth bet against Abbott MitraClip and TriClip, Medtronic and emerging edge to edge and replacement systems. Management commentary into summer 2026 framed PASCAL, EVOQUE and SAPIEN M3 momentum as the driver of the TMTT acceleration (per edwards.com, July 2026).
- Surgical structural heart: INSPIRIS, INSPIRIS RESILIA with RESILIA tissue and VFit technology, KONECT RESILIA conduit and MITRIS RESILIA. Surgery grows slower but defends the referral funnel and funds conversion to TAVR over time, competing with Medtronic, Abbott and Artivion surgical valves.
Recurring versus one time economics
There is no razor and blade here, no capital box and no service contract. Every valve is one time per patient, priced as a high value implant, but recurring at the hospital and system level because aortic stenosis, mitral regurgitation and tricuspid disease are progressive, underdiagnosed and age driven. Volume comes from new diagnoses, expanded screening, referral from surgery to TAVR, and share gains from clinical data, not from replacements or upgrades. That makes Edwards a procedure volume compounder: gross margin was 77.8%, operating margin was 29.8% and profit margin was 15.4% on yfinance, with FY2025 operating income of $1.26B and net income of $1.07B on XBRL facts. The cost is commercial and clinical, with research and development of $1.08B in FY2025, up from $903.10M in FY2021, to fund successive SAPIEN generations, PASCAL and EVOQUE iterations and RESILIA tissue science.
Strategy and competitive flywheel
Edwards strategy is focus as a weapon. It divested non structural heart distractions, concentrated all $1.08B of R and D on valves, then turns evidence into volume. Superior hemodynamics and durability data drive guidelines and heart team confidence, confidence drives training and proctoring demand, training locks in the direct sales relationship, and installed physician preference funds the next trial and the next device. That loop showed in 2026 when management pointed to proactive disease management and SAPIEN durability alongside broad TAVR adoption as reasons to lift the full year constant currency outlook (per edwards.com, July 2026). Scale then drops through: operating cash flow was $1.60B in 2025 against capital expenditure of only $260.20M, producing free cash flow of $1.33B, with $2.94B of cash against only $705.40M of total debt and $598.30M of long term debt. Edwards recycles that cash into innovation and buybacks, repurchasing $893.40M of stock in 2025 after $1.16B in 2024. The bear case is concentration: one aortic franchise, pricing pressure from Medtronic and Abbott, and a 52.62 trailing price to earnings ratio versus 26.13 forward that leaves no room for a TAVR slowdown. The bull case is that the installed base, at $88.40 versus a $101.81 analyst mean target and a $59.70 to $130.68 five year range, still underprices TMTT becoming a second TAVR.
| Engine | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Revenue, XBRL | $6.00B | $1.39B | $6.07B |
| Operating income, XBRL | $1.53B | $1.38B | $1.26B |
| R and D, XBRL | $1.07B | $1.05B | $1.08B |
Segments & Products
Edwards Lifesciences is a pure play structural heart company, with FY2025 revenue of $6.07B, gross margin of 77.8% and operating margin of 29.8%, valued at $50.90B at $88.40 per share with 16,000 employees. It sells only to advanced cardiovascular disease, principally aortic, mitral and tricuspid valve disease, in the United States, Europe, Japan and internationally through a direct sales force and independent distributors. The economics are those of an implant annuity: a $1.74B second quarter, up 13.6% year over year, with TAVR at $1.26B, up 11.3%, per edwards.com, July 2026.
| Franchise | Flagship products | What it does |
|---|---|---|
| Transcatheter Aortic Valve Replacement | Edwards SAPIEN family | Minimally invasive replacement of the aortic valve |
| Transcatheter Mitral and Tricuspid Therapies | PASCAL, EVOQUE, SAPIEN M3 | Edge to edge repair and transcatheter replacement for mitral and tricuspid disease |
| Surgical Structural Heart | INSPIRIS, INSPIRIS RESILIA, KONECT RESILIA, MITRIS RESILIA | Surgical aortic and mitral valves and conduits for complex combined procedures |
The three franchises
TAVR is the engine. SAPIEN, a balloon expandable valve, accounted for roughly seven in ten dollars of sales in the second quarter, at $1.26B of the $1.74B total, per edwards.com, July 2026. Constant currency growth of 10.5% in that quarter shows a mature franchise still compounding at high single to low double digits, with management raising 2026 constant currency TAVR guidance to 8% to 9%, per edwards.com, July 2026. The moat is clinical evidence and iteration, from PARTNER 3 to EARLY TAVR durability data cited on the second quarter call, per finance.yahoo.com, July 2026, against Medtronic Evolut and CoreValve self expanding platforms and Abbott Navitor, named as primary TAVR competitors per csimarket.com, October 2026.
TMTT is the growth option turning into a business. PASCAL competes head to head with Abbott MitraClip G4 in edge to edge repair, while EVOQUE, FDA cleared in February 2024 alongside Abbott TriClip in April 2024, opened the first dedicated tricuspid replacement market, per eureka.patsnap.com, September 2026. Coverage of the quarter put TMTT at $195.9M, up 44.8%, with PASCAL, EVOQUE and SAPIEN M3 all contributing, and full year guidance of $760M to $780M, per finance.yahoo.com, July 2026. That is still under 12% of the $6.07B FY2025 base, which is why incremental beats matter more here than in TAVR.
Surgical is the cash compounder. INSPIRIS RESILIA with RESILIA tissue and VFit technology, KONECT RESILIA pre assembled conduit, and MITRIS RESILIA anchor a business growing mid single digits, with second quarter surgical sales of $284M, up 5%, supported by RESILIA data and U.S. approval of the Eclipse surgical left atrial appendage device, per finance.yahoo.com, July 2026. Medtronic and Abbott are again the named surgical competitors, per csimarket.com, October 2026.
End markets and pricing power
The customer is the heart team, not the general hospital, which explains the 77.8% gross margin and 29.8% operating margin on $6.07B of sales and the willingness to fund $1.08B of FY2025 research and development. Edwards prices on outcomes, hemodynamics, durability and reintervention risk, validated in trials such as CLASP IID and TRISCEND II against Abbott COAPT and TRILUMINATE, per eureka.patsnap.com, September 2026. Direct reps in labs, proctored cases and valve sizing support lock in share in a concentrated oligopoly where regulatory and clinical validation are the barrier, a structure described as concentrated among a few integrated OEMs, per indexbox.io, October 2026.
Growth drivers
- Aortic stenosis penetration: proactive disease management and asymptomatic indication expansion keep converting surgical candidates and watchful waiting patients to SAPIEN.
- Mitral and tricuspid untapped pools: TEER, TMVR and TTVR bring transcatheter options to patients long deemed untreatable, with portfolio breadth across PASCAL, EVOQUE and SAPIEN M3 as the differentiator versus single device rivals.
- RESILIA tissue cycle: durability claims extend surgical relevance even as TAVR grows, defending the combined $1.74B quarterly base.
Operations & Go-to-Market
Edwards Lifesciences is a structural heart pure play headquartered in Irvine, California, founded in 1958 and run with 16000 employees supporting $6.07B of FY2025 revenue. The operating model is concentrated, not diversified: design, tissue science and final assembly for high value valves, plus a clinically intensive direct sales force that lives in the cath lab and operating room. That focus shows up in the P and L, with a 77.8% gross margin and 29.8% operating margin, FY2025 operating income of $1.26B on that $6.07B revenue base, and $2.94B of cash against only $705.40M of total debt on $13.70B of assets.
Manufacturing and delivery footprint
Core manufacturing and R and D are anchored in Irvine, where about 5,100 of its nearly 16,000 employees work at its expansive Irvine campus, per ocbj.com, June 2026. That co location matters because surgical and transcatheter valves are not commodity devices. RESILIA tissue processing, leaflet matching, valve crimping and delivery system assembly require cleanroom handwork and tight iteration between engineers and manufacturing, funded by $1.08B of FY2025 research and development expense. Commercial delivery is global across the United States, Europe, Japan and internationally, but fulfillment is center based rather than broad retail distribution. Product ships to a limited set of high volume heart centers, where Edwards fields inventory, sizing tools, delivery catheters and proctors for first cases. Capital intensity is modest for a device maker of this margin profile, with FY2025 capital expenditure of $260.20M and operating cash flow of $1.60B, which is the signature of tissue and catheter assembly, not heavy metals or semiconductor fabs.
Distribution and sales model
Edwards distributes through a direct sales force and independent distributors, with the United States and Europe carried overwhelmingly direct. This is a procedure sale, not a box sale. Reps support patient screening, CT sizing, valve selection and lab staffing, and they train interventional cardiologists, cardiac surgeons, imaging specialists and valve clinic coordinators as a team. That team sale is why Edwards defends share against Medtronic in aortic valve replacement and against Abbott and Boston Scientific in mitral and tricuspid repair despite hospital contracting pressure. Momentum remains TAVR led, with second quarter sales of $1.74 billion including TAVR sales of $1.26 billion, per edwards.com, July 2026, while transcatheter mitral and tricuspid therapies and surgical valves provide the second and third legs in the same call point. Management under Bernard Zovighian, who took over as CEO in 2023, per ocbj.com, June 2026, has sharpened that story by exiting slower Critical Care operations to concentrate field resources entirely on structural heart.
- Direct clinical selling: territory specialists paired with clinical proctors drive new center activation, case support and referral development for SAPIEN, PASCAL and EVOQUE.
- Distributor fill in: independent distributors cover smaller or more distant markets in Japan and internationally where a full direct team is uneconomic.
- Center concentration: selling effort targets TAVR, TMTT and surgical programs in the same hospital, letting one relationship carry aortic, mitral, tricuspid and surgical pipelines.
Vertical integration and geographic exposure
Edwards is vertically integrated where it creates pricing power and outsourced where it does not. It owns valve design, RESILIA and VFit tissue platforms, delivery catheter design and physician education, which protects the 77.8% gross margin and supports premium pricing for INSPIRIS, KONECT RESILIA, MITRIS RESILIA, SAPIEN, PASCAL and EVOQUE systems. It does not own hospitals, imaging equipment or home care, it partners into them. Geographic exposure is explicitly stated as the United States, Europe, Japan and internationally, which operationally means four different reimbursement clocks for the same device. The U.S. is the volume and price anchor for TAVR, Europe is the early adoption ground for PASCAL and EVOQUE technique development, and Japan and rest of world add regulatory and tender complexity managed partly through distributors. With $10.34B of stockholders equity, $3.36B of liabilities and long term debt of only $598.30M, Edwards can fund that global center by center build without balance sheet strain, and the 13.6% revenue growth rate indicates the field model is still adding productive centers rather than harvesting old ones.
| Platform | Flagship brands | Go to market motion |
|---|---|---|
| Transcatheter aortic replacement | SAPIEN family | Direct U.S. and Europe team sale, screening to implant support |
| Mitral and tricuspid repair and replacement | PASCAL, EVOQUE | Proctored rollout, imaging led center activation |
| Surgical structural heart | INSPIRIS, KONECT RESILIA, MITRIS RESILIA | Surgeon direct sale, complex procedure conduit |
Financials
Edwards Lifesciences is a high gross margin compounder working through a noisy earnings base. Revenue was $6.07B in FY2025 per EDGAR, matching Total Revenue of $6.07B per yfinance. The yfinance series shows Total Revenue of $4.46B in 2022, $5.01B in 2023, $5.44B in 2024 and $6.07B in 2025, with reported revenue growth of 13.6% per yfinance. EDGAR reports ResearchAndDevelopmentExpense of $1.08B in FY2025, $1.05B in FY2024 and $1.07B in FY2023, and OperatingIncomeLoss of $1.26B in FY2025, $1.38B in FY2024 and $1.53B in FY2023. Momentum continued into 2026, with second quarter sales of $1.74B, up 13.6% year over year on TAVR sales of $1.26B and adjusted EPS of $0.78 per sec.gov, July 2026, while full year constant currency sales growth guidance was raised to 10% to 11% per quartr.com, August 2026.
Margins, EPS and returns
Profitability is elite at the gross line and thinner below it on a trailing basis. Gross margin was 77.8%, operating margin was 29.8% and profit margin was 15.4% per yfinance. Gross Profit was $4.73B in 2025, $4.32B in 2024 and $4.03B in 2023 per yfinance. Operating Income was $1.64B in 2025, $1.48B in 2024 and $1.49B in 2023 per yfinance. Net Income was $1.07B in 2025, $4.17B in 2024 and $1.40B in 2023 per yfinance, so the 2024 spike explains the optically demanding trailing P/E of 52.62 versus a forward P/E of 26.13 per yfinance. Diluted EPS was $1.83 in 2025, $6.97 in 2024 and $2.30 in 2023 per yfinance. Returns were ROE of 9.2% and ROA of 8.4% per yfinance, with EBITDA of $1.45B in 2025, $1.72B in 2024 and $1.53B in 2023 per yfinance, supporting EV/EBITDA of 23.79 per yfinance.
| Line, all figures per yfinance | 2023 | 2024 | 2025 |
|---|---|---|---|
| Total Revenue | $5.01B | $5.44B | $6.07B |
| Gross Profit | $4.03B | $4.32B | $4.73B |
| Operating Income | $1.49B | $1.48B | $1.64B |
| Net Income | $1.40B | $4.17B | $1.07B |
| Diluted EPS | $2.30 | $6.97 | $1.83 |
| Free Cash Flow | $629.50M | $259.90M | $1.33B |
Balance sheet, cash flow and capital allocation
The balance sheet is net cash and conservatively levered. Cash And Cash Equivalents were $2.94B in FY2025 and $3.05B in FY2024 per EDGAR, matching $2.94B and $3.05B per yfinance. Total Debt was $705.40M in 2025 and $700.00M in 2024 per yfinance, with Long Term Debt of $598.30M in 2025 and $597.70M in 2024 per yfinance. Total Assets were $13.70B in 2025 and $13.06B in 2024 per EDGAR and per yfinance. Total Liabilities Net Minority Interest were $3.36B in 2025 and $2.99B in 2024 per yfinance, matching Liabilities of $3.36B and $2.99B per EDGAR. Stockholders Equity was $10.34B in 2025 and $10.00B in 2024 per EDGAR and per yfinance. Free cash flow was $1.23B on the current snapshot per yfinance, while the cash flow statement shows Free Cash Flow of $1.33B in 2025, $259.90M in 2024 and $629.50M in 2023 per yfinance, on Operating Cash Flow of $1.60B, $542.30M and $895.80M per yfinance. Capital allocation favors buybacks over dividends, with no dividend disclosed in the pack. Repurchase Of Capital Stock was -$893.40M in 2025, -$1.16B in 2024 and -$879.60M in 2023 per yfinance, alongside Capital Expenditure of -$260.20M, -$282.40M and -$266.30M per yfinance.
Revenue & net income by fiscal year ($B)
Margin trend by fiscal year
Competitive Landscape & Moat
Edwards Lifesciences is the pure play in structural heart, with FY2025 revenue of $6.07B, gross margin of 77.8% and operating income of $1.26B. At $88.40, the company carries a market cap of $50.90B and an enterprise value of $47.51B, priced at a trailing P/E of 52.62, a forward P/E of 26.13 and EV/EBITDA of 23.79. That premium, against an analyst target mean of $101.81, reflects a narrow but deep moat in valves where clinical evidence, training and regulation matter more than price.
TAVR remains a two horse race
The core battle is Edwards SAPIEN versus Medtronic Evolut/CoreValve. Per cardiacwire.com, May 2026, SAPIEN 3 holds 55-60% U.S. share against Evolut at 30-35%, with Abbott Navitor/Portico a distant third. Medtronic counters with self expanding nitinol breadth, a pulmonary valve in Harmony and global scale. Edwards counters with balloon expandable precision, SAPIEN 3 Ultra RESILIA and long term durability data that management cites as driving procedure growth, per edwards.com, July 2026. Surgical still matters: INSPIRIS RESILIA, KONECT RESILIA and MITRIS RESILIA defend the referral funnel against LivaNova, Corcym, MicroPort and Meril Life Sciences, a group named among the ten major cardiac valve competitors per marketresearch.com, December 2025.
Mitral and tricuspid is where the moat gets tested
In mitral repair, Abbott MitraClip is the installed base leader, built over nearly two decades. Edwards answers with PASCAL Precision. In replacement, the field is now FDA sanctioned on both sides: Abbott Tendyne, approved May 2025 for severe mitral annular calcification, and Edwards SAPIEN M3, approved December 2025 for transseptal replacement, per mordorintelligence.com, June 2026 and giiresearch.com, June 2026. Tricuspid is earlier and more open. Edwards EVOQUE has first mover advantage in replacement, supported by 2 year TRISCEND II durability data in March 2026, per giiresearch.com, June 2026, while Abbott pushes edge to edge repair and JenaValve, HighLife and Boston Scientific chase valve in valve and transseptal niches. Edwards raised full year TMTT guidance after Q2 sales strength across PASCAL, EVOQUE and SAPIEN M3, per edwards.com, July 2026, a sign the portfolio is scaling beyond TAVR.
| Player | TAVR position | Mitral/Tricuspid position | Structural heart edge |
|---|---|---|---|
| Edwards | SAPIEN leader, U.S. benchmark | PASCAL, EVOQUE, SAPIEN M3 | Pure play focus, RESILIA tissue, direct sales force |
| Medtronic | Evolut No. 2, self expanding | Broad pipeline, scale distribution | Diversified portfolio, mapping plus ablation stack |
| Abbott | Navitor/Portico No. 3 | MitraClip leader, Tendyne approved | Repair installed base, global reach |
| Boston Scientific / J&J MedTech | Challengers, regional share | Repair and replacement entrants | Scale, acquisition capacity |
Why the moat endures
Switching costs are clinical, not contractual. TAVR and TMTT require heart team training, imaging protocols, sizing and proctoring. Once a center standardizes on SAPIEN sizing, delivery and post dilations, switching to Evolut or Navitor retrains physicians on a live valve case. That risk aversion sustains share and supports 77.8% gross margin and 29.8% operating margin.
Regulation and evidence are barriers. Valves travel the PMA path with multi year pivotal trials and durability follow up. Edwards funds that with FY2025 R&D of $1.08B and a balance sheet holding $2.94B in cash against only $705.40M in total debt and equity of $10.34B. With 16,000 employees and a direct sales force plus independent distributors, it converts trials into adoption faster than JenaValve or HighLife can replicate.
Where Edwards lags: diversification. Medtronic, Abbott and Boston Scientific can bundle, absorb price pressure and fund losses in mitral and tricuspid from electrophysiology or rhythm businesses. Edwards, at $6.07B in sales, must win every valve cycle. The 5 year return of negative 24.2% against a 1 year return of 16.3%, with a 5 year range of $59.70 to $130.68 and a 52 week range of $74.66 to $96.29, shows what happens when TAVR growth pauses. The bull case is that EVOQUE and PASCAL plus SAPIEN M3 turn a TAVR company into a four pillaralled TAVR, mitral, tricuspid and surgical compounder.
Verdict & Valuation
Verdict: Buy. At $88.40, for a $50.90B market cap and $47.51B enterprise value, Edwards is a washed out compounder with a newly derisked second franchise, not a melting TAVR monopoly. The stock is up 16.3% over one year but still down 24.2% over five years, trading $7.89 below its $96.29 52 week high and far below its five year $59.70 to $130.68 range. Trailing P and E of 52.62 is optical, priced on depressed diluted EPS of $1.83 and net income of $1.07B versus $6.97 and $4.17B in 2024, while forward P and E of 26.13 and EV to EBITDA of 23.79 pay for 13.6% revenue growth at 77.8% gross margin with net cash. The Street at $101.81 with a buy recommendation implies about 15% upside, which is fair for 10% to 11% constant currency growth with operating leverage finally set to return.
| Snapshot | Figure |
|---|---|
| Price, Oct 21 2026 | $88.40 |
| Market cap and enterprise value | $50.90B and $47.51B |
| Trailing P and E, forward P and E, EV to EBITDA | 52.62, 26.13, 23.79 |
| 52 week range and analyst target | $74.66 to $96.29, $101.81 |
| FY2025 revenue, gross margin, operating margin | $6.07B, 77.8%, 29.8% |
| Cash versus total debt | $2.94B versus $705.40M |
Why the bull wins at $88.40
Scale with acceleration. SEC XBRL revenue was $6.07B in FY2025 versus $6.00B in FY2023 and $5.38B in FY2022, and yfinance revenue growth is 13.6%. That came from the Edwards SAPIEN family for minimally invasive aortic replacement, sold by a direct sales force plus distributors and supported by 16000 employees. The June quarter confirmed reacceleration, with Q2 sales of $1.74B up 13.6% reported and 12.5% in constant currency and TAVR sales of $1.26B up 11.3% reported and 10.5% in constant currency (per edwards.com, July 2026), with adjusted EPS of $0.78 beating forecasts of $0.74 on $1.70B (per investing.com, July 2026). Management then raised 2026 constant currency growth to 10% to 11% for the total company and 8% to 9% for TAVR, pointing to total sales of $6.6B to $6.9B and TAVR sales of $4.75B to $5.0B with adjusted EPS of $2.95 to $3.05 and Q3 sales of $1.63B to $1.71B (per investing.com, July 2026).
Gross margin funds the moat. Gross margin of 77.8% with profit margin of 15.4% and R and D of $1.08B in FY2025 versus $1.05B in FY2024 sustains SAPIEN iterations plus INSPIRIS RESILIA, KONECT RESILIA and MITRIS RESILIA surgical extensions. Medtronic sells Evolut FX scale, Abbott sells MitraClip, TriClip, Tendyne and Navitor breadth, Boston Scientific sells Acurate neo2 and WATCHMAN adjacency, but none matches Edwards in aortic surgical plus transcatheter breadth. Competitive intensity has now shifted to portfolio breadth across repair and replacement (per eureka.patsnap.com, Sept 2026), where Abbott and Edwards control the commercial layer through MitraClip G4, PASCAL Precision, TriClip and the EVOQUE system.
TMTT is no longer option value. FDA approved the PASCAL Precision system for tricuspid repair to improve quality of life and functional status in symptomatic severe regurgitation (per edwards.com, Oct 2026), making Edwards the only U.S. company offering transcatheter repair and replacement for both mitral and tricuspid valves (per ocbj.com, Oct 2026). That turns PASCAL plus EVOQUE plus SAPIEN M3 from a $195.9M style quarter into a five therapy company spanning TAVR, PASCAL repair, EVOQUE replacement, mitral replacement and surgery, the explicit path to long term 10% average growth.
What the bear gets right, and why it is survivable
Operating leverage has run in reverse. SEC XBRL operating income fell to $1.26B in FY2025 from $1.53B in FY2023 and $1.75B in FY2022 while revenue rose from $5.38B to $6.07B, and net income was $1.07B in FY2025 versus $1.40B in FY2023, with XBRL net of $385.60M in FY2024. ROE of 9.2% and ROA of 8.4% are thin for 26.13 times forward earnings and 23.79 times EV to EBITDA. Concentration is extreme, the quarter still belongs to TAVR at more than 70% of sales, and rivals can discount systems and fund trials through EP, rhythm and occlusion bundles.
The balance sheet buys time for the inflection. FY2025 ended with cash of $2.94B versus total debt of $705.40M including long term debt of $598.30M, with total assets of $13.70B against liabilities of $3.36B for equity of $10.34B versus $10.00B in FY2024. Operating cash flow recovered to $1.60B from $542.30M in 2024 and free cash flow to $1.33B from $259.90M in 2024 and $629.50M in 2023, with yfinance free cash flow at $1.23B, funding $893.40M of repurchases in 2025 after $1.16B in 2024 and $879.60M in 2023. That is a fortress that can sustain $1.08B of R and D while TMTT scales.
What would change the view
- TAVR deceleration below the raised bar. If constant currency TAVR growth slips back toward mid single digits and total company growth falls below the 10% to 11% 2026 guide, from $6.6B to $6.9B, the 26.13 forward multiple has no cover. A 200 basis point share loss to Medtronic Evolut or Abbott Navitor, or pricing pressure in the cath lab, would confirm the pure play discount.
- No leverage on the TMTT ramp. If XBRL operating income stays stuck near $1.26B and net stays near $1.07B despite $1.08B of R and D and PASCAL tricuspid plus EVOQUE scale, the 77.8% gross to 29.8% operating conversion is structural, not investment. Then $88.40, only $7.89 below $96.29, is full, and the $101.81 target falls.
The Bull Case
- TAVR compounder reaccelerating at scale Edwards did $6.07B of revenue in FY2025 on XBRL filings with 13.6% year over year revenue growth, built on the Edwards SAPIEN family for minimally invasive aortic replacement sold through a direct sales force plus distributors and supported by 16000 employees. Per edwards.com, July 2026, management raised full year sales growth guidance after a strong Q2 led by TAVR, and per ir.edwards.com, Feb 2026, management pointed to PARTNER 3 seven year, PARTNER 2 ten year and EARLY TAVR durability data plus updated European guidelines as multiyear procedure catalysts against Medtronic Evolut and Abbott Navitor generalists.
- 77.8% gross margin funds a structural heart R&D moat Gross margin of 77.8% with operating margin of 29.8% and profit margin of 15.4% leaves room to spend while compounding, with R and D of $1.08B in FY2025 versus $1.05B in FY2024 and operating income of $1.26B on XBRL filings. That reinvestment sustains SAPIEN iterations plus INSPIRIS RESILIA, KONECT RESILIA and MITRIS RESILIA surgical extensions, a full stack response that Abbott with MitraClip repair focus and Boston Scientific with WATCHMAN and valve adjacencies cannot match in aortic surgical plus transcatheter breadth.
- TMTT is a second Edwards inside the P and L PASCAL and EVOQUE for mitral and tricuspid repair and replacement turn a one franchise aortic company into a five therapy company spanning TAVR, PASCAL repair, EVOQUE replacement, SAPIEN M3 mitral replacement and surgery. Per edwards.com, Oct 2026, FDA approved the PASCAL Precision system for tricuspid repair to improve quality of life and functional status in symptomatic severe regurgitation, and per ocbj.com, Oct 2026, that approval makes Edwards the only U.S. company offering transcatheter repair and replacement for both mitral and tricuspid valves.
- Fortress balance sheet that buys back stock every year FY2025 ended with cash of $2.94B versus total debt of $705.40M including long term debt of $598.30M, with total assets of $13.70B against liabilities of $3.36B for equity of $10.34B versus $10.00B in FY2024 on XBRL filings. That conservatism converts, with operating cash flow of $1.60B and free cash flow of $1.33B funding $893.40M of capital stock repurchases in 2025 after $1.16B in 2024, while net income recovered to $1.07B in FY2025 from $385.60M in FY2024.
- Washed out five year chart with an earnings inflection At $88.40 on Oct 21, 2026, the stock is up 16.3% over one year but still down 24.2% over five years, trading below the 52 week high of $96.29 and far below the five year high of $130.68 after ranging from $59.70 to $130.68. The reset shows in multiples, with trailing P and E of 52.62 collapsing to forward P and E of 26.13 and EV to EBITDA of 23.79 on enterprise value of $47.51B and market cap of $50.90B, while the Street target of $101.81 with a buy recommendation prices TMTT and next generation TEER as growth, not option value.
The Bear Case
- Valuation prices perfection on mid single digit economics: At $88.40, a $50.90B market cap and $47.51B enterprise value, Edwards trades at 52.62 times trailing earnings, 26.13 times forward earnings and 23.79 times EV to EBITDA. That is a growth multiple for a business earning 9.2% ROE and 8.4% ROA, with a 15.4% profit margin, sitting only $7.89 below its $96.29 52 week high and still down 24.2% on a 5 year basis from a $130.68 peak high to a $59.70 low range. The Street target of $101.81 leaves little error margin if TAVR decelerates, and the current $88.40 price already assumes the bull case on mitral and tricuspid.
- Operating leverage is running in reverse: SEC XBRL revenue was $6.07B in FY2025, up from $6.00B in FY2023 and $5.38B in FY2022, while yfinance puts 2025 revenue at $6.07B versus $5.44B in 2024 and $5.01B in 2023. Yet SEC XBRL operating income fell to $1.26B in FY2025 from $1.53B in FY2023 and $1.75B in FY2022. Net income was $1.07B in FY2025 versus $1.40B in FY2023, and diluted EPS collapsed to $1.83 in 2025 from $6.97 in 2024 on net income of $1.07B versus $4.17B. A 77.8% gross margin converting to a 29.8% operating margin tells the story, R and D consumed $1.08B in 2025 and $1.05B in 2024 without restoring leverage.
- Extreme concentration in one procedure, SAPIEN TAVR: The company description is SAPIEN for aortic replacement, PASCAL and EVOQUE for mitral and tricuspid, plus INSPIRIS, KONECT RESILIA and MITRIS RESILIA surgical valves. In practice the quarter still belongs to TAVR. Per sec.gov, July 2026, Q2 sales were $1.74B with TAVR at $1.26B, or more than 70% of the quarter, growing 11.3% reported and 10.5% in constant currency. Management then raised 2026 constant currency guidance to only 8% to 9% for TAVR and 10% to 11% for the total company, per sec.gov, July 2026. If aortic pricing, volumes or share slip by 200 basis points, there is no other scale franchise to offset it.
- A focused pure play against diversified predators: Edwards has 16000 employees and one structural heart bet. Medtronic sells Evolut FX and CoreValve, Abbott sells MitraClip, TriClip, Tendyne and Navitor, Boston Scientific sells Acurate neo2 and Watchman, all with broader EP, rhythm, occlusion and surgical bundles. Per eureka.patsnap.com, September 2026, Edwards and Medtronic split the TAVR duopoly while Boston Scientific and Abbott keep pressure on price and iteration cadence, and Boston Scientific missed non inferiority with Acurate neo2 versus SAPIEN and Evolut which only sharpens the next generation race. A $300M Innovalve style tuck in, noted per mordorintelligence.com, does not match rivals who can discount systems, fund trials and absorb a lost quarter.
- Cyclical cath lab exposure with fragile cash conversion: Revenue growth of 13.6% year over year looks smooth, cash flow does not. Free cash flow was $1.33B in 2025 versus only $259.90M in 2024 and $629.50M in 2023, operating cash flow was $1.60B in 2025 versus $542.30M in 2024, while yfinance free cash flow sits at $1.23B. Meanwhile Edwards repurchased $893.40M of stock in 2025 after $1.16B in 2024 and $879.60M in 2023, funded from a $2.94B cash pile against $705.40M of total debt and $598.30M of long term debt. Any deferral of elective structural procedures, reimbursement squeeze or hospital capital freeze turns that buyback from support at $88.40 into balance sheet fragility.
Key Risks
- TAVR concentration: Edwards lives on one franchise, SAPIEN aortic replacement, so any slowdown in aortic volumes hits $6.07B in FY2025 revenue directly.
- Structural heart oligopoly fightback: Medtronic Evolut, Abbott MitraClip and Portico, and Boston Scientific ACURATE attack the 77.8% gross margin from all sides.
- TMTT scale up or stall: PASCAL and EVOQUE mitral and tricuspid bets consume a $1.08B R and D budget before they can diversify growth.
- Reimbursement and hospital throughput: Procedure deferral or price resets turn high fixed cost cath lab leverage into operating deleverage.
- Premium multiple with memory: At $88.40, a trailing P and E of 52.62, forward P and E of 26.13 and EV and EBITDA of 23.79 leave no cushion, with a 5y return of -24.2%.
1. Single franchise leverage to TAVR
Edwards is a pure play structural heart company built around the Edwards SAPIEN family for minimally invasive aortic replacement, plus INSPIRIS RESILIA, KONECT RESILIA and MITRIS RESILIA surgical valves. Q2 showed the skew, with total sales of $1.74B and TAVR sales of about $1.3B, per sec.gov, July 2026 and per finance.yahoo.com, July 2026. On a FY2025 base of $6.07B in revenue and $1.07B in net income, with $13.70B in assets against $3.36B in liabilities, that concentration magnifies any pause in screening, referrals, staffing, or aortic valve pricing. Management lifted 2026 constant currency guidance to 10% to 11% total and 8% to 9% for TAVR, per sec.gov, July 2026, which raises the bar it must clear every quarter.
What would confirm this risk: TAVR constant currency growth prints below the 8% to 9% guided range for two quarters while total growth falls toward high single digits.
2. Medtronic, Abbott and Boston Scientific take share
Edwards is described as holding 60 to 65% of the U.S. TAVR market and 55 to 60% globally with SAPIEN 3 Ultra RESILIA, per theindextimes.com, July 2026, a lead that invites attack from Medtronic CoreValve and Evolut, Abbott Portico and MitraClip, and Boston Scientific ACURATE neo2. Q2 benefited in part from a competitor exit, per alphaspread.com, July 2026, a one time help that will not repeat. The threat is not only aortic, Abbott contests mitral repair with MitraClip against PASCAL, while Medtronic and Boston Scientific contest aortic, pulmonary and left atrial appendage adjacencies. With a $50.90B market cap and $47.51B enterprise value, share loss of even 200 to 300 basis points forces price, trial and salesforce spending against a 77.8% gross margin and 29.8% operating margin structure.
What would confirm this risk: Evolut FX Plus or ACURATE neo2 wins two consecutive U.S. share surveys while Edwards TAVR grows below the market despite stable procedures.
3. TMTT does not scale fast enough to diversify
Transcatheter mitral and tricuspid repair and replacement under PASCAL and EVOQUE is the designated second leg, alongside SAPIEN M3, but it starts small and clinically demanding. Q2 TMTT sales surged to $195.9M, per perplexity.ai, July 2026, still a fraction of a $6.07B company funding $1.08B in FY2025 R and D. Edwards funds that pipeline from $2.94B in cash against $705.40M in total debt and $598.30M in long term debt, plus $1.23B in free cash flow, so the balance sheet at $10.34B in equity can pay, but time is the cost. Slow enrollment, mixed durability data, or limited transfemoral adoption leaves TAVR carrying the 13.6% revenue growth expectation alone.
What would confirm this risk: TMTT quarterly sales stall near $200M for three quarters while R and D stays above $1.00B annualized without a new approval.
4. Pricing, reimbursement and procedure cadence
Structural heart is a hospital capacity product sold through a direct sales force and distributors, sensitive to cath lab staffing, DRG and outpatient payment, and country level reimbursement variation. A 77.8% gross margin, 15.4% profit margin, 9.2% ROE and 8.4% ROA profile assumes premium pricing for SAPIEN, PASCAL, EVOQUE and RESILIA tissue technology holds. U.S. pressure on device prices, European tendering, Japan biennial cuts, or a shift of isolated aortic cases to watchful waiting compresses that stack quickly because the cost base of 16000 employees, clinical specialists and $1.08B in R and D does not flex. The Q1 contrast was instructive, Edwards raised while both Abbott and Boston Scientific cut 2026 guidance, per medtechdive.com, April 2026, a divergence that can reverse if hospitals slow capital and procedure scheduling.
What would confirm this risk: Gross margin falls for two straight quarters while surgical sales near $284M, per perplexity.ai, July 2026, decelerate to low single digits on hospital delays.
5. Multiple compression on any miss
At $88.40, versus a 52 week range of $74.66 to $96.29 and a 5 year range of $59.70 to $130.68, Edwards trades at 52.62 times trailing earnings, 26.13 times forward earnings and 23.79 times EV and EBITDA, against a $101.81 mean target and a buy rating. The 1 year return of 16.3% has repaired sentiment, but the 5 year return of negative 24.2% shows what multiple reset looks like when TAVR decelerated before. Adjusted EPS guidance of $2.95 to $3.05, per sec.gov, July 2026, already embeds 150 basis points of constant currency operating margin expansion and absorbs FX pressure on gross margins, per investing.com, July 2026, so a revenue miss drops straight to the bottom line and to buyback capacity after $893.40M in FY2025 repurchases.
What would confirm this risk: The stock falls more than 10% on a quarter where sales meet but adjusted EPS misses, and forward P and E rerates toward large cap medtech peers.
Lessons
1. Gross margin is the strategy, not the result
Edwards posts 77.8% gross margin and 29.8% operating margin on a yfinance basis, with $6.07B of FY2025 revenue and $1.26B of FY2025 operating income in the SEC 10-K XBRL facts. That spread funds $1.08B of FY2025 research and development, or nearly one dollar of R and D for every six dollars of sales, to defend SAPIEN, PASCAL, EVOQUE and INSPIRIS. Unlike diversified device conglomerates that compete on scale and distribution, a pure play valve company competes on tissue science and clinical data, and only that margin structure can sustain it.
2. Screeners lie, 10-Ks do not
yfinance shows net income of $4.17B in 2024 collapsing to $1.07B in 2025, with diluted EPS falling from $6.97 to $1.83, while the 10-K XBRL facts show NetIncomeLoss of $385.60M in FY2024 rising to $1.07B in FY2025. The market prices that confusion at a trailing P/E of 52.62 against a forward P/E of 26.13. Lesson: normalize for divestitures, one time gains and share count before paying a growth multiple, and always reconcile the screener to EDGAR.
3. Net cash plus buybacks beats leverage in procedure driven medtech
Edwards holds $2.94B in cash against $705.40M of total debt and $598.30M of long term debt, so enterprise value of $47.51B sits below a $50.90B market cap. With $1.23B of free cash flow, it repurchased $893.40M of stock in 2025, building stockholders equity to $10.34B on $13.70B of assets against $3.36B of liabilities. At 9.2% ROE and 8.4% ROA, the compounding comes from a fortress balance sheet and shrinking float, not financial engineering.
4. Focus creates the moat, then caps the multiple
At $88.40, Edwards is down from a 5 year high of $130.68, with a 5 year return of -24.2% despite 13.6% year over year revenue growth, trading between $74.66 and $96.29 over 52 weeks against a $101.81 analyst mean target. The narrow aortic, mitral and tricuspid franchise makes Edwards the innovation leader, but every catheter lab slowdown is a company slowdown. Lesson: pay for dominance only when procedure growth, not just pricing, justifies EV/EBITDA of 23.79.